Total Payments
$344.69
2024 Payments
$209.60
Companies
10
Transactions
14
Medicare Patients
2,157
Medicare Billing
$597,850
Payment Breakdown by Category
Food & Beverage$242.27 (70.3%)
Education$102.42 (29.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $242.27 | 12 | 70.3% |
| Education | $102.42 | 2 | 29.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| BeiGene USA, Inc. | $81.42 | 1 | $0 (2022) |
| PFIZER INC. | $60.46 | 3 | $0 (2024) |
| ABBVIE INC. | $39.25 | 2 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $30.77 | 1 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $30.50 | 2 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $25.64 | 1 | $0 (2024) |
| Eisai Inc. | $22.51 | 1 | $0 (2024) |
| Mirati Therapeutics, Inc. | $21.00 | 1 | $0 (2023) |
| Sobi, Inc | $17.63 | 1 | $0 (2022) |
| Merck Sharp & Dohme LLC | $15.51 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $209.60 | 10 | PFIZER INC. ($60.46) |
| 2023 | $36.04 | 2 | Mirati Therapeutics, Inc. ($21.00) |
| 2022 | $99.05 | 2 | BeiGene USA, Inc. ($81.42) |
All Payment Transactions
14 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/04/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $22.51 | General |
| Category: Oncology | ||||||
| 11/07/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $27.34 | General |
| Category: ONCOLOGY | ||||||
| 09/26/2024 | PFIZER INC. | LORBRENA (Drug), BRAFTOVI, MEKTOVI | Food and Beverage | In-kind items and services | $18.47 | General |
| Category: ONCOLOGY | ||||||
| 08/22/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $25.64 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 07/26/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $21.24 | General |
| Category: ONCOLOGY | ||||||
| 06/20/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $15.46 | General |
| Category: Cardiovascular | ||||||
| 05/30/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $30.77 | General |
| Category: Oncology | ||||||
| 03/28/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $18.01 | General |
| Category: ONCOLOGY | ||||||
| 01/17/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $15.51 | General |
| Category: ONCOLOGY | ||||||
| 01/03/2024 | PFIZER INC. | INLYTA (Drug), XTANDI, TALZENNA | Food and Beverage | In-kind items and services | $14.65 | General |
| Category: ONCOLOGY | ||||||
| 12/07/2023 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $15.04 | General |
| Category: Cardiovascular | ||||||
| 03/16/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Education | In-kind items and services | $21.00 | General |
| Category: ONCOLOGY | ||||||
| 08/12/2022 | BeiGene USA, Inc. | BRUKINSA (Drug) | Education | In-kind items and services | $81.42 | General |
| Category: Oncology | ||||||
| 07/29/2022 | Sobi, Inc | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $17.63 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 26 | 1,159 | 33,907 | $1.7M | $460,575 |
| 2022 | 20 | 794 | 4,435 | $548,686 | $117,787 |
| 2021 | 8 | 204 | 736 | $78,034 | $19,488 |
Total Patients
2,157
Total Services
39,078
Medicare Billing
$597,850
Procedure Codes
54
All Medicare Procedures & Services
54 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 13 | 7,601 | $1.1M | $319,123 | 29.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 189 | 398 | $77,818 | $26,811 | 34.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 116 | 179 | $77,347 | $23,527 | 30.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 47 | 196 | $72,374 | $19,910 | 27.5% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 76 | 761 | $86,974 | $17,128 | 19.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 99 | 154 | $45,632 | $14,702 | 32.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 53 | 100 | $20,314 | $6,046 | 29.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 30 | 30 | $17,295 | $4,970 | 28.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 49 | 99 | $20,934 | $4,858 | 23.2% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 11 | 10,200 | $30,600 | $3,779 | 12.4% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 18 | 67 | $12,065 | $3,375 | 28.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 26 | 26 | $11,532 | $3,281 | 28.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 30 | 30 | $11,900 | $2,951 | 24.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 17 | 43 | $4,171 | $1,897 | 45.5% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 20 | 66 | $5,126 | $1,433 | 28.0% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 24 | 116 | $6,908 | $1,401 | 20.3% |
| J1453 | Injection, fosaprepitant, 1 mg | Office | 2023 | 23 | 11,100 | $55,500 | $1,376 | 2.5% |
| 96411 | Administration of additional new drug or substance into vein using push technique | Office | 2023 | 12 | 28 | $4,712 | $1,212 | 25.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 48 | 96 | $6,508 | $1,052 | 16.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 12 | 12 | $3,888 | $872.70 | 22.4% |
| J9045 | Injection, carboplatin, 50 mg | Office | 2023 | 13 | 208 | $21,840 | $405.82 | 1.9% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 58 | 190 | $380.00 | $150.56 | 39.6% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 65 | 1,284 | $3,852 | $124.64 | 3.2% |
| J3490 | Unclassified drugs | Office | 2023 | 55 | 153 | $21,420 | $94.82 | 0.4% |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | Office | 2023 | 31 | 737 | $8,844 | $56.56 | 0.6% |
About Philip Brandt
Philip Brandt is a Hematology & Oncology healthcare provider based in Fredericksburg, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/31/2015. The National Provider Identifier (NPI) number assigned to this provider is 1578949681.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Philip Brandt has received a total of $344.69 in payments from pharmaceutical and medical device companies, with $209.60 received in 2024. These payments were reported across 14 transactions from 10 companies. The most common payment nature is "Food and Beverage" ($242.27).
As a Medicare-enrolled provider, Brandt has provided services to 2,157 Medicare beneficiaries, totaling 39,078 services with total Medicare billing of $597,850. Data is available for 3 years (2021–2023), covering 54 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Fredericksburg, VA
- Active Since 07/31/2015
- Last Updated 07/28/2023
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1578949681
Products in Payments
- BRUKINSA (Drug) $81.42
- INLYTA (Drug) $41.99
- LUTATHERA (Drug) $30.77
- ZEPZELCA (Drug) $25.64
- Lenvima (Drug) $22.51
- VENCLEXTA (Drug) $21.24
- KRAZATI (Drug) $21.00
- LORBRENA (Drug) $18.47
- EPKINLY (Drug) $18.01
- DOPTELET (Drug) $17.63
- KEYTRUDA (Biological) $15.51
- ELIQUIS (Drug) $15.46
- CAMZYOS (Drug) $15.04
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Fredericksburg
Dr. Sudeep Menachery, Md, MD
Hematology & Oncology — Payments: $43,555
Hematology & Oncology $43,555
Dr. Christopher Vaughn, M.d, M.D
Hematology & Oncology — Payments: $25,364
Hematology & Oncology $25,364
Dr. Lakshminarayanan Nandagopal
Hematology & Oncology — Payments: $13,537
Hematology & Oncology $13,537
Dr. Charles Maurer, Md, MD
Hematology & Oncology — Payments: $12,694
Hematology & Oncology $12,694
Lisa Simmons, Md, MD
Hematology & Oncology — Payments: $10,038
Hematology & Oncology $10,038
Ms. Bonny Moore, Md, MD
Hematology & Oncology — Payments: $8,111
Hematology & Oncology $8,111